Subscribe To

Price Alert Latest News Economic Calendar News

CVS / Walgreens and CVS among companies warned by FDA against marketing unapproved eye products

The US Food and Drug Administration (FDA) has issued warning letters to eight companies including Walgreens Boots Alliance Inc (NASDAQ:WBA) and CVS Health Corp (NYSE:CVS) for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. The eye products addressed in the eight warning letters are illegally marketed to treat conditions such as conjunctivitis (pink eye), cataracts, glaucoma and others, The FDA said in a news release. Read More

Demo Live Account See Partner Details

Content Topics

Walgreens

Among

Companies

Warned

Against

Marketing

Unapproved

Products

Stock

CVS

Posted: Sep 13 2023, 08:56

Author Name: Proactive Investors

CVS News

By The Motley Fool
November 3, 2023

CVS Health Is Down 27% This Year. Is the Stock a Buy on the Dip?

CVS Health stock dipped after the company reported third-quarter results on Nov. 1. CVS Health's largest operating segment lost a big client earlier t

By Market Watch
November 2, 2023

FDA's eye-drops recall: The full list of CVS, Walmart, Target and Rite Aid products that you should stop using ASAP

The list of over-the-counter eye drops that the Food and Drug Administration warns could lead to serious infections continues to grow, with the federa

By Reuters
November 1, 2023

CVS and Walgreens say pharmacist work action had minimal impact

CVS Health Corp and Walgreens Boots Alliance on Wednesday said that a work action by some U.S. pharmacists this week had minimal impact on operations,

By The Motley Fool
November 1, 2023

Why CVS Health Stock Dropped Today

CVS Health delivered better-than-expected revenue and earnings for its third quarter of 2023. The pharmacy chain also lowered its full-year earnings o

By Zacks Investment Research
November 1, 2023

CVS Health (CVS) Q3 Earnings Surpass Estimates, Margins Up

Robust sales growth across all three operating segments drove CVS Health's (CVS) third-quarter results.

By Investopedia
November 1, 2023

CVS's Results Beat Forecasts, but Shares Fall as It Cuts Full-Year Unadjusted EPS

CVS Health (CVS) posted better-than-expected results on gains in its health services business, but shares fell 1% in early trading Wednesday as the bi

By Proactive Investors
November 1, 2023

CVS shares drop 4.2% on guidance downgrade

CVS Health Corp (NYSE:CVS) bobbed and weaved to put the best gloss on its third-quarter earnings update early on – only to see the stock flop 4.2% p

By Forbes
November 1, 2023

CVS Health Profits Eclipse $2.2 Billion As Company Integrates New Provider Businesses

CVS Health reported third quarter net income of $2.2 billion thanks in part to contributions from its new healthcare services acquisitions.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.